Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis drug shows promise for teens in early trial

NCT ID NCT04718896

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two doses of bimekizumab, a drug that targets inflammation, in 41 adolescents aged 12 to 17 with moderate to severe plaque psoriasis. The main goals were to measure how the drug behaves in the body and to check its safety. Researchers also looked at how well it cleared skin plaques over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bimekizumab
What this could lead to
If successful, this could provide a new treatment option for teenagers with moderate to severe plaque psoriasis, helping clear their skin and improve quality of life.
What could go wrong
This is a small, early-phase trial (41 participants) focused on drug levels and safety, not yet proving long-term effectiveness. Side effects are possible, and results may not apply to all teens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE PLAQUE PSORIASIS

Contacts and locations

Locations

  • Ps0020 40333

    Wroclaw, Poland

  • Ps0020 40334

    Wroclaw, Poland

  • Ps0020 40335

    Warsaw, Poland

  • Ps0020 40396

    Rzeszów, Poland

  • Ps0020 40625

    Lodz, Poland

  • Ps0020 40626

    Bialystok, Poland

  • Ps0020 40645

    Frankfurt, Germany

  • Ps0020 50344

    Indianapolis, Indiana, 46250, United States

  • Ps0020 50354

    Calgary, Canada

  • Ps0020 50357

    St. John's, Canada

  • Ps0020 50359

    Cypress, Texas, 77433, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.